摘要
目的探讨老年晚期非小细胞肺癌(NSCLC)患者在接受抗程序性死亡受体-1(PD-1)免疫治疗后细胞因子水平与治疗效果的相关性,并评估细胞因子生物标志物预测治疗反应的效能。方法选择2021年10月至2023年6月收治的60例老年晚期NSCLC患者,患者均接受4个周期的抗PD-1免疫治疗,根据疗效将其分为有效组和无效组。比较老年晚期NSCLC患者治疗前、后的细胞因子水平;比较无效组和有效组患者的细胞因子水平;分析细胞因子水平预测治疗反应的效能。结果治疗后,患者的白细胞介素-2(IL-2)水平高于治疗前,白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)水平低于治疗前(P<0.05)。有效组的IL-2水平高于无效组,IL-4、IL-6、IL-10水平低于无效组,差异具有统计学意义(P<0.05)。受试者工作特性(ROC)曲线分析显示,IL-2、IL-4、IL-6和IL-10水平对老年晚期NSCLC患者抗PD-1免疫治疗反应的预测效能较好,曲线下面积(AUC)分别为0.71、0.64、0.75和0.62。结论IL-2和IL-4、IL-6、IL-10水平与老年晚期NSCLC患者抗PD-1免疫治疗反应密切相关,尤其是IL-6低水平可能预示较好疗效。
Objective To investigate the correlation between cytokine levels and therapeutic effects after anti-programmed cell death receptor-1(PD-1)immunotherapy in elderly patients with advanced non-small cell lung cancer(NSCLC),and to evaluate the efficacy of cytokine biomarkers in predicting treatment response.Methods A total of 60 elderly patients with advanced NSCLC from October 2021 to June 2023 were selected.All patients received 4 cycles of anti-PD-1 immunotherapy.According to the efficacy,the patients were divided into effective group and ineffective group.The levels of cytokines before and after treatment in elderly patients with advanced NSCLC were compared;the cytokine levels of patients in the ineffective group and the effective group were compared;the efficacy of cytokine levels in predicting treatment response was analyzed.Results After treatment,the level of interleukin-2(IL-2)was higher than that before treatment,and the levels of interleukin-4(IL-4),interleukin-6(IL-6)and interleukin-10(IL-10)were lower than those before treatment(P<0.05).The level of IL-2 in the effective group was higher than that in the ineffective group,and the levels of IL-4,IL-6 and IL-10 were lower than those in the ineffective group,and the differences were statistically significant(P<0.05).Receiver operating characteristic(ROC)curve analysis showed that the levels of IL-2,IL-4,IL-6 and IL-10 had a good predictive effect on the response of anti-PD-1 immunotherapy in elderly patients with advanced NSCLC,the area under the curve(AUC)was 0.71,0.64,0.75 and 0.62,respectively.Conclusion The levels of IL-2,IL-4,IL-6 and IL-10 are closely related to the response of anti-PD-1 immunotherapy in elderly patients with advanced NSCLC,especially the low level of IL-6 may indicate better efficacy.
作者
孙军
吴大山
郑皆红
杨俊昌
SUN Jun;WU Dashan;ZHENG Jiehong;YANG Junchang(Geriatrics Medicine Department,Jianhu Clinical Medical College,Yangzhou University,Yancheng 224700;Jianhu Clinical College,Jiangsu Vocational College of Medicine,Yancheng 224700;Oncology Department,Jianhu Clinical Medical College,Yangzhou University,Yancheng 224700,China)
出处
《临床医学研究与实践》
2025年第27期64-67,共4页
Clinical Research and Practice
基金
江苏医药职业学院2022年度建湖临床学院科研项目(No.20229JH29)。
关键词
非小细胞肺癌
老年
免疫治疗
程序性死亡受体-1
细胞因子
预测效能
non-small cell lung cancer
elderly
immunotherapy
programmed cell death receptor-1
cytokine
prediction efficiency
